TRPC5 and breast cancer: The identification of specific L-EVs, in fact, can be the distinctive of chemoresistant tumor cells as occur for TrpC5+ L-EVs that were demonstrated in metastatic BC patients following adriamycin-based chemotherapy, while being undetectable in chemotherapy naïve patients [59].